4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-methylthiopyrimidine | 334893-07-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-methylthiopyrimidine
• 英文别名: 4-[5-(3-Fluoro-5-morpholinobenzamido)-2-methylanilino]2-methylthiopyrimidine；3-fluoro-N-[4-methyl-3-[(2-methylsulfanylpyrimidin-4-yl)amino]phenyl]-5-morpholin-4-ylbenzamide
• CAS: 334893-07-1
• 化学式: C₂₃H₂₄FN₅O₂S
• 分子量: 453.54
• InChiKey: IGADPVQMANOWFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-methylthiopyrimidine 在 sodium tungstate 、 双氧水 作用下， 以 异丁酰胺 为溶剂， 反应 22.0h， 生成 4-[5-(3-fluoro-5-morpholinobenzamido)-2-methylanilino]-2-methylsulphonylpyrimidine
  参考文献：
  名称：

  PYRIMIDINE DERIVATIVES

  摘要：

  公开号：

  EP1226126B1

文献信息

• Pyrimidine derivatives
  申请人：Cumming John Graham

  公开号：US06846827B1

  公开（公告）日：2005-01-25

  The invention concerns pyrimidine derivatives of Formula (I) wherein m is 0-3 and each R 1 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R 3 is hydrogen, halogeno or (1-6C)alkyl; n is 0-2 and each R 2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; p is 0-4; and Q 1 is aryl or heteroaryl; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及式（I）的嘧啶衍生物，其中m为0-3，每个R1是羟基，卤素，三氟甲基和氰基等基团；R3为氢，卤素或（1-6C）烷基；n为0-2，每个R2是羟基，卤素，三氟甲基和氰基等基团；p为0-4；Q1为芳基或杂环芳基；或其药学上可接受的盐或体内可裂解的酯；其制备方法，包含它们的制药组合物以及它们在治疗细胞因子介导的疾病或医学状况中的应用。
• PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS
  申请人：Jung Birgit

  公开号：US20100099651A1

  公开（公告）日：2010-04-22

  The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK 1 antagonists, anticholinergics and endothelin antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.
• US6846827B1
  申请人：——

  公开号：US6846827B1

  公开（公告）日：2005-01-25
• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2001027089A1

  公开（公告）日：2001-04-19

  The invention concerns pyrimidine derivatives of Formula (I) wherein m is 0-3 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R3 is hydrogen, halogeno or (1-6C)alkyl; n is 0-2 and each R2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; p is 0-4; and Q1 is aryl or heteroaryl; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
• PYRIMIDINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1226126B1

  公开（公告）日：2005-01-05